Multi-Organs-on-Chips: Towards Long-Term Biomedical Investigations
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
With advantageous features such as minimizing the cost, time, and sample size requirements, organ-on-a-chip (OOC) systems have garnered enormous interest from researchers for their ability for real-time monitoring of physical parameters by mimicking the in vivo microenvironment and the precise responses of xenobiotics, i.e., drug efficacy and toxicity over conventional two-dimensional (2D) and three-dimensional (3D) cell cultures, as well as animal models. Recent advancements of OOC systems have evidenced the fabrication of ‘multi-organ-on-chip’ (MOC) models, which connect separated organ chambers together to resemble an ideal pharmacokinetic and pharmacodynamic (PK-PD) model for monitoring the complex interactions between multiple organs and the resultant dynamic responses of multiple organs to pharmaceutical compounds. Numerous varieties of MOC systems have been proposed, mainly focusing on the construction of these multi-organ models, while there are only few studies on how to realize continual, automated, and stable testing, which still remains a significant challenge in the development process of MOCs. Herein, this review emphasizes the recent advancements in realizing long-term testing of MOCs to promote their capability for real-time monitoring of multi-organ interactions and chronic cellular reactions more accurately and steadily over the available chip models. Efforts in this field are still ongoing for better performance in the assessment of preclinical attributes for a new chemical entity. Further, we give a brief overview on the various biomedical applications of long-term testing in MOCs, including several proposed applications and their potential utilization in the future. Finally, we summarize with perspectives.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
The third dimension bridges the gap between cell culture and live tissue
Pampaloni, F., Reynaud, E. G., & Stelzer, E. H. K. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2236 · Cited by 2,817
From 3D cell culture to organs-on-chips
Huh, D., Hamilton, G. A., & Ingber, D. E. (2011) · Trends in Cell Biology · doi:10.1016/j.tcb.2011.09.005 · Cited by 1,834
Organoid Cultures Derived from Patients with Advanced Prostate Cancer
Gao, D., Vela, I., Sboner, A., Iaquinta, P. J., Karthaus, W. R., Gopalan, A., Dowling, C., Wanjala, J. N., Undvall, E. A., Arora, V. K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.016 · Cited by 1,559
Microscale culture of human liver cells for drug development
Khetani, S. R., & Bhatia, S. N. (2008) · Nature Biotechnology · doi:10.1038/nbt1361 · Cited by 1,219
Tong, R. T., Boucher, Y., Kozin, S. V., Winkler, F., Hicklin, D. J., & Jain, R. K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0074 · Cited by 1,189
Organs-on-chips at the frontiers of drug discovery
Esch, E. W., Bahinski, A., & Huh, D. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4539 · Cited by 1,185 · cited 1×
“More often, the OOC systems are preferred over conventional approaches to precisely record drug performances with minimal resources in terms of time and cost, so that these models have gained popularity in the fields of therapeutic development over the past years [14,40,59,126,127].”
BackgroundMaschmeyer, I., Lorenz, A. K., Schimek, K., Hasenberg, T., Ramme, A. P., Hübner, J., Lindner, M., Drewell, C., Bauer, S., Thomas, A., et al. (2015) · Lab on a Chip · doi:10.1039/c5lc00392j · Cited by 861
Zhang, Y. S., Aleman, J., Shin, S. R., Kilic, T., Kim, D., Mousavi Shaegh, S. A., Massa, S., Riahi, R., Chae, S., Hu, N., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612906114 · Cited by 833
The use of 3-d cultures for high-throughput screening: the multicellular spheroid model.
Kunz-Schughart, L. A., Freyer, J. P., Hofstaedter, F., & Ebner, R. (2004) · SLAS DISCOVERY · doi:10.1177/1087057104265040 · Cited by 797
Organs-on-a-Chip: A Fast Track for Engineered Human Tissues in Drug Development
Ronaldson-Bouchard, K., & Vunjak-Novakovic, G. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.02.011 · Cited by 657
Multi-tissue interactions in an integrated three-tissue organ-on-a-chip platform
Skardal, A., Murphy, S. V., Devarasetty, M., Mead, I., Kang, H.-W., Seol, Y.-J., Shrike Zhang, Y., Shin, S.-R., Zhao, L., Aleman, J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-08879-x · Cited by 623 · cited 1×
“In a recent study, an MOC system comprising lung tissues based on the PDMS model and bioprinted spherical liver and heart organoids, which were connected via a central fluid channel with fluid flow driven by a peristaltic micropump has been established, and the effects of bleomycin were determined by utilizing ELISA t…”
MethodFundamentals of microfluidic cell culture in controlled microenvironments
Young, E. W. K., & Beebe, D. J. (2010) · Chemical Society Reviews · doi:10.1039/b909900j · Cited by 615
Pluripotent stem cells in disease modelling and drug discovery
Avior, Y., Sagi, I., & Benvenisty, N. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2015.27 · Cited by 592
A microfluidic 3D in vitro model for specificity of breast cancer metastasis to bone
Bersini, S., Jeon, J. S., Dubini, G., Arrigoni, C., Chung, S., Charest, J. L., Moretti, M., & Kamm, R. D. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.11.050 · Cited by 534
Organoid-on-a-chip and body-on-a-chip systems for drug screening and disease modeling
Skardal, A., Shupe, T., & Atala, A. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.07.003 · Cited by 512 · cited 3×
“Prescribed treatments are usually based on the general success rate of drugs, rather than the response of specific patients to drugs; thus, efficient tools in support of predicting how a specific individual responds to a drug are greatly needed [155,159,160].”
BackgroundWagner, I., Materne, E.-M., Brincker, S., Süßbier, U., Frädrich, C., Busek, M., Sonntag, F., Sakharov, D. A., Trushkin, E. V., Tonevitsky, A. G., et al. (2013) · Lab on a Chip · doi:10.1039/c3lc50234a · Cited by 476 · cited 3×
“Particularly, in some studies, researchers have paid more attention toward long-term cultivation and continual testing by using MOCs [12,46,129,143].”
BackgroundHassell, B. A., Goyal, G., Lee, E., Sontheimer-Phelps, A., Levy, O., Chen, C. S., & Ingber, D. E. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.043 · Cited by 467
Organ-on-a-chip devices advance to market
Zhang, B., & Radisic, M. (2017) · Lab on a Chip · doi:10.1039/c6lc01554a · Cited by 437
Organ/body-on-a-chip based on microfluidic technology for drug discovery
Kimura, H., Sakai, Y., & Fujii, T. (2018) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2017.11.003 · Cited by 435 · cited 1×
“To fill the gap between in vivo and in vitro conditions, microfluidic approaches have been utilized in OOC technology to simulate organ functions by facilitating the effective transportation [67].”
MethodOxygen gradients correlate with cell density and cell viability in engineered cardiac tissue
Radisic, M., Malda, J., Epping, E., Geng, W., Langer, R., & Vunjak‐Novakovic, G. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20722 · Cited by 399
Muratore, C. R., Rice, H. C., Srikanth, P., Callahan, D. G., Shin, T., Benjamin, L. N. P., Walsh, D. M., Selkoe, D. J., & Young-Pearse, T. L. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu064 · Cited by 379 · cited 1×
“Alternatively, MEAs technology has been extensively used in electrophysiological experiments for monitoring the electrochemical signals in disease modeling of heart or nerve systems [113,114], drug testing [115], and toxicological models [116,117] in vitro, and it has been used to convey electric currents to cells in…”
MethodXu, Z., Li, E., Guo, Z., Yu, R., Hao, H., Xu, Y., Sun, Z., Li, X., Lyu, J., & Wang, Q. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b08746 · Cited by 264
Skardal, A., Devarasetty, M., Forsythe, S., Atala, A., & Soker, S. (2016) · Biotechnology and Bioengineering · doi:10.1002/bit.25950 · Cited by 230
Organs-on-a-chip: a new tool for drug discovery
Polini, A., Prodanov, L., Bhise, N. S., Manoharan, V., Dokmeci, M. R., & Khademhosseini, A. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.886562 · Cited by 223
Organ-on-chip models of cancer metastasis for future personalized medicine: From chip to the patient
Caballero, D., Kaushik, S., Correlo, V. M., Oliveira, J. M., Reis, R. L., & Kundu, S. C. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.10.005 · Cited by 221
Systematic reviews of animal models: methodology versus epistemology
Greek, R., & Menache, A. (2013) · International Journal of Medical Sciences · doi:10.7150/ijms.5529 · Cited by 207
Microfluidic Organ‐on‐a‐Chip Technology for Advancement of Drug Development and Toxicology
Caplin, J. D., Granados, N. G., James, M. R., Montazami, R., & Hashemi, N. (2015) · Advanced Healthcare Materials · doi:10.1002/adhm.201500040 · Cited by 205
van Midwoud, P. M., Merema, M. T., Verpoorte, E., & Groothuis, G. M. M. (2010) · Lab on a Chip · doi:10.1039/c0lc00043d · Cited by 203
Imura, Y., Sato, K., & Yoshimura, E. (2010) · Analytical Chemistry · doi:10.1021/ac100806x · Cited by 172 · cited 1×
“Due to the strong desire for a thorough and accurate in vitro assessment of drug potency in the processing of cancer therapeutics, multi-organ/tissue systems have emerged as a potential tool for drug screening [5,60,135,136].”
BackgroundBiomimetic 3D tissue models for advanced high-throughput drug screening
Nam, K.-H., Smith, A. S. T., Lone, S., Kwon, S., & Kim, D.-H. (2015) · SLAS Technology · doi:10.1177/2211068214557813 · Cited by 171
A microfluidic platform for quantitative analysis of cancer angiogenesis and intravasation
Lee, H., Park, W., Ryu, H., & Jeon, N. L. (2014) · Biomicrofluidics · doi:10.1063/1.4894595 · Cited by 130
3D spherical microtissues and microfluidic technology for multi-tissue experiments and analysis
Kim, J.-Y., Fluri, D. A., Marchan, R., Boonen, K., Mohanty, S., Singh, P., Hammad, S., Landuyt, B., Hengstler, J. G., Kelm, J. M., et al. (2015) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2015.01.003 · Cited by 126
Microfluidic devices for in vitro studies on liver drug metabolism and toxicity
van Midwoud, P. M., Verpoorte, E., & Groothuis, G. M. M. (2011) · Integrative Biology · doi:10.1039/c0ib00119h · Cited by 115
Ho, W. J., Pham, E. A., Kim, J. W., Ng, C. W., Kim, J. H., Kamei, D. T., & Wu, B. M. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01723.x · Cited by 115 · cited 1×
“Due to the strong desire for a thorough and accurate in vitro assessment of drug potency in the processing of cancer therapeutics, multi-organ/tissue systems have emerged as a potential tool for drug screening [5,60,135,136].”
BackgroundLee, J. B., & Sung, J. H. (2013) · Biotechnology Journal · doi:10.1002/biot.201300086 · Cited by 92 · cited 1×
“The inaccurate prediction of the PK-PD profile of any drug can increase the failure rate of its development process [53,54].”
BackgroundWang, X.-Y., Pei, Y., Xie, M., Jin, Z.-H., Xiao, Y.-S., Wang, Y., Zhang, L.-N., Li, Y., & Huang, W.-H. (2015) · Lab on a Chip · doi:10.1039/c4lc00973h · Cited by 77
Bioprinting and organ-on-chip applications towards personalized medicine for bone diseases
Arrigoni, C., Gilardi, M., Bersini, S., Candrian, C., & Moretti, M. (2017) · Stem Cell Reviews and Reports · doi:10.1007/s12015-017-9741-5 · Cited by 68
The ability of animal studies to detect serious post marketing adverse events is limited
van Meer, P. J. K., Kooijman, M., Gispen-de Wied, C. C., Moors, E. H. M., & Schellekens, H. (2012) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2012.09.002 · Cited by 66
A microfluidic model for organ-specific extravasation of circulating tumor cells
Riahi, R., Yang, Y. L., Kim, H., Jiang, L., Wong, P. K., & Zohar, Y. (2014) · Biomicrofluidics · doi:10.1063/1.4868301 · Cited by 60 · cited 1×
“The discovery of novel anti-cancer and diagnostic tools [146] has been progressing steadily by revealing the specific signals of the cancer microenvironment and affecting the tumor growth, malignancy [147–151], and transvascular migration [152,153].”
BackgroundSelf-contained, low-cost Body-on-a-Chip systems for drug development
Wang, Y. I., Oleaga, C., Long, C. J., Esch, M. B., McAleer, C. W., Miller, P. G., Hickman, J. J., & Shuler, M. L. (2017) · Experimental Biology and Medicine · doi:10.1177/1535370217694101 · Cited by 59 · cited 1×
“Termed as ‘multi-organ-on-chip’ (MOC), sometimes referred as ‘body-on-a-chip (BOC)’, this device combining microscale technology with mathematical PK-PD modeling has separate chambers connected by microfluidic flow channels precisely emulating blood circulation, which provides an approach for monitoring the dynamic re…”
BackgroundMattei, F., Schiavoni, G., De Ninno, A., Lucarini, V., Sestili, P., Sistigu, A., Fragale, A., Sanchez, M., Spada, M., Gerardino, A., et al. (2014) · Journal of Immunotoxicology · doi:10.3109/1547691x.2014.891677 · Cited by 57
Organ-, body-and disease-on-a-chip systems
Shuler, M. L. (2017) · Lab on a Chip · doi:10.1039/c7lc90068f · Cited by 54
Zou, H., Yue, W., Yu, W.-K., Liu, D., Fong, C.-C., Zhao, J., & Yang, M. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b00873 · Cited by 47
Cited by
Organ-on-a-chip: recent breakthroughs and future prospects
Wu, Q., Liu, J., Wang, X., Feng, L., Wu, J., Zhu, X., Wen, W., & Gong, X. (2020) · BioMedical Engineering OnLine · doi:10.1186/s12938-020-0752-0 · Cited by 701
The multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528
Multiorgan-on-a-Chip: A Systemic Approach To Model and Decipher Inter-Organ Communication
Picollet-D’hahan, N., Zuchowska, A., Lemeunier, I., & Le Gac, S. (2021) · Trends in Biotechnology · doi:10.1016/j.tibtech.2020.11.014 · Cited by 379
Desai, N., Rana, D., Patel, M., Bajwa, N., Prasad, R., & Vora, L. K. (2025) · Small · doi:10.1002/smll.202502315 · Cited by 295
Trujillo-de Santiago, G., Flores-Garza, B. G., Tavares-Negrete, J. A., Lara-Mayorga, I. M., González-Gamboa, I., Zhang, Y. S., Rojas-Martínez, A., Ortiz-López, R., & Álvarez, M. M. (2019) · Materials · doi:10.3390/ma12182945 · Cited by 184
“Human-on-chips systems that recapitulate not only the tumor niche but also one or more possible target metastasis organs connected throughout a vascular/fluidic network—will be a highly valuable tool for proper modeling of metastasis [99,223,224].”
Background
Metadata
- Authors
- Zhao, Y., Kankala, R. K., Wang, S.-B., & Chen, A.-Z.
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2019-02-14
- Volume
- 24
- Issue
- 4
- Pages
- 675
- ISSN
- 1420-3049 (ISSN-L)
- OpenAlex
- W2914731860
- Cited by
- 134
- References
- 45
- FWCI
- 5.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.